[go: up one dir, main page]

MX2024007451A - Metodos de tratamiento de enfermedades neoplasicas. - Google Patents

Metodos de tratamiento de enfermedades neoplasicas.

Info

Publication number
MX2024007451A
MX2024007451A MX2024007451A MX2024007451A MX2024007451A MX 2024007451 A MX2024007451 A MX 2024007451A MX 2024007451 A MX2024007451 A MX 2024007451A MX 2024007451 A MX2024007451 A MX 2024007451A MX 2024007451 A MX2024007451 A MX 2024007451A
Authority
MX
Mexico
Prior art keywords
methods
neoplastic diseases
treating neoplastic
compound
formula
Prior art date
Application number
MX2024007451A
Other languages
English (en)
Inventor
Heidi Lane
Felix Bachmann
Karine Litherland
Guido Zaman
Original Assignee
Sillajen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sillajen Inc filed Critical Sillajen Inc
Publication of MX2024007451A publication Critical patent/MX2024007451A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona un compuesto de fórmula (I) o una sal farmacéuticamente aceptable del mismo como se define en las reivindicaciones para utilizarse en el tratamiento de una enfermedad neoplásica en un sujeto, donde el tratamiento comprende administrar el compuesto de fórmula (I) o una sal farmacéuticamente aceptable del mismo al sujeto de acuerdo a un programa de dosificación intermitente.
MX2024007451A 2021-12-15 2022-12-14 Metodos de tratamiento de enfermedades neoplasicas. MX2024007451A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21214941 2021-12-15
EP22191429 2022-08-22
PCT/KR2022/020392 WO2023113478A1 (en) 2021-12-15 2022-12-14 Methods of treating neoplastic diseases

Publications (1)

Publication Number Publication Date
MX2024007451A true MX2024007451A (es) 2024-07-09

Family

ID=86773108

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007451A MX2024007451A (es) 2021-12-15 2022-12-14 Metodos de tratamiento de enfermedades neoplasicas.

Country Status (8)

Country Link
US (1) US20250057844A1 (es)
EP (1) EP4448528A4 (es)
JP (1) JP2024546977A (es)
KR (1) KR20240107329A (es)
AU (1) AU2022408915A1 (es)
CA (1) CA3241111A1 (es)
MX (1) MX2024007451A (es)
WO (1) WO2023113478A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102076689B (zh) * 2008-06-26 2014-10-15 内尔维阿诺医学科学有限公司 吡唑并-喹唑啉类
WO2012101032A1 (en) * 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
EA201600002A1 (ru) * 2013-06-11 2016-06-30 Байер Фарма Акциенгезельшафт Производные пролекарства замещенных триазолопиридинов
CN106132963B (zh) * 2014-04-07 2019-08-06 荷兰转化研究中心有限责任公司 (5,6-二氢)嘧啶并[4,5-e]吲嗪
US10611765B2 (en) * 2014-11-06 2020-04-07 Ohio State Innovation Foundation Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors
ES2966392T3 (es) * 2015-04-17 2024-04-22 Crossfire Oncology Holding B V Biomarcadores pronósticos para quimioterapia inhibidora de TTK
WO2019002542A1 (en) * 2017-06-30 2019-01-03 Les Laboratoires Servier COMBINATION OF AN INHIBITOR OF MPS1 AND A TAXANE COMPOUND, USES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME

Also Published As

Publication number Publication date
EP4448528A1 (en) 2024-10-23
JP2024546977A (ja) 2024-12-26
US20250057844A1 (en) 2025-02-20
AU2022408915A1 (en) 2024-06-27
CA3241111A1 (en) 2023-06-22
WO2023113478A1 (en) 2023-06-22
KR20240107329A (ko) 2024-07-09
EP4448528A4 (en) 2025-10-22

Similar Documents

Publication Publication Date Title
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
NZ777871A (en) Small molecule modulators of il-17
MX2021001752A (es) Compuestos de pirrolo-dipiridina.
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
MY200810A (en) Pyrrolidine compounds
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MY199779A (en) Pyrrolopyrimidine compound and use thereof
ZA202401684B (en) Novel parp7 inhibitor and use thereof
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
MX2024003952A (es) Combinación que comprende atogepant para tratar la migraña.
SI1594885T1 (sl) Zdravilo za inhibiranje rasti tumorjev
WO2023081482A9 (en) Combination of a bile acid and a phenyl butyrate compound for the treatment of neurodegenerative diseases
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
WO2020128614A8 (en) Method for treating interstital lung disease
MX2021001710A (es) Compuestos de fluoro ?-carbolina.
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
EA202193211A1 (ru) Лечение синуклеопатий
EP4620940A3 (en) Synthesis of (+)-cannabinoids and their therapeutic effects
MX2024007451A (es) Metodos de tratamiento de enfermedades neoplasicas.